Ardelyx to Participate in Three Upcoming Investor Conferences in September

Rhea-AI Summary

Ardelyx, Inc. (Nasdaq: ARDX) announced its participation in three investor conferences in September 2020. The first event is Citi's 15th Annual BioPharma Virtual Conference on September 9. Then, they will present at the 22nd Annual H.C. Wainwright Global Investment Conference on September 14 at 5:00 p.m. E.T., followed by the Cantor Fitzgerald Global Healthcare Conference on September 17 at 12:40 p.m. E.T. Webcasts of the presentations will be available on Ardelyx's website, with replays for 30 days post-conference.

FREMONT, Calif., Sept. 8, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Ardelyx management will participate in three upcoming investor conferences in September including:

• Citi's 15^th Annual BioPharma Virtual Conference on Wednesday, September 9^th
• 22nd Annual H.C. Wainwright Global Investment Conference on Monday, September 14^th with a presentation at 5:00 p.m. E.T.
• Cantor Fitzgerald Global Healthcare Conference 2020 on Thursday, September 17^th with a presentation at 12:40 p.m. E.T.

Both the H.C. Wainwright and Cantor Fitzgerald conference presentations will be available via webcast. To access the live webcasts of Ardelyx's presentations, please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcasts will be available on the Ardelyx website for 30 days following each conference.

About Ardelyx, Inc.
Ardelyx is a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases. The Ardelyx pipeline includes tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, for which an NDA is under review by the FDA, and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx received FDA approval of IBSRELA^® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in the respective territories.

View original content to download multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-participate-in-three-upcoming-investor-conferences-in-september-301124705.html

SOURCE Ardelyx

FAQ

What investor conferences will Ardelyx participate in September 2020?

Ardelyx will participate in Citi's 15th Annual BioPharma Virtual Conference on September 9, H.C. Wainwright Global Investment Conference on September 14, and Cantor Fitzgerald Global Healthcare Conference on September 17.

When is Ardelyx's presentation at the H.C. Wainwright conference?

Ardelyx's presentation at the H.C. Wainwright conference is scheduled for September 14, 2020, at 5:00 p.m. E.T.

Where can I access Ardelyx's conference presentations?

Ardelyx's conference presentations can be accessed via webcast on the Events & Presentations page of their Investor section at ir.ardelyx.com.

How long will the webcasts of Ardelyx's presentations be available?

The webcasts of Ardelyx's presentations will be available for replay on their website for 30 days following each conference.

What is Ardelyx focused on developing?

Ardelyx focuses on developing innovative first-in-class medicines for kidney and cardiovascular diseases.